The Oncology Institute announced that it received written notice from the Listing Qualifications Staff of The Nasdaq Stock Market on September 15, 2023, informing the Company that it has regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 550(a)(2) for continued listing on the Nasdaq Capital Market. To regain compliance with the Rule, the Company’s common shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days. This requirement was met on September 14, 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TOI:
- The Oncology Institute Regains Compliance with Nasdaq Listing Requirements
- Ambience Healthcare and The Oncology Institute (TOI) Partner to Create a Best-in-Class Oncology Experience for Patients and Clinicians, Leveraging Breakthrough Generative AI Technology
- The Oncology Institute, Ambience Healthcare announce new agreement
- The Oncology Institute Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance
- The Oncology Institute partners with House Rx for integration
